23andMe

Sunnyvale, United States Founded: 2006 • Age: 20 yrs Acquired By TTAM Research Institute
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
Annual revenue $189.9M Latest available
Total funding $943.5M 21 rounds
Employees 265 Tracked headcount
Investors 21 Known backers
Products 3 Services tracked
Competitors 10 Brand Intelligence

About 23andMe

23andMe is a company based in Sunnyvale (United States) founded in 2006 was acquired by TTAM Research Institute in June 2025. 23andMe has raised $943.53 million across 21 funding rounds from investors including Google, Fidelity Investments and Illumina. The company has 265 employees as of March 31, 2024. 23andMe has completed 2 acquisitions, including CureTogether and Icebreaker Health. 23andMe offers products and services including Ancestry Service, Health + Ancestry Service, and 23andMe Premium. 23andMe operates in a competitive market with competitors including Ancestry, Color, Veritas Genetics, Genoplan and GEDmatch, among others.

  • Headquarter Sunnyvale, United States
  • Employees 265 as on 31 Mar, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name 23Andme Holding Co.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $189.9 M (USD)
    -13.54
    as on Mar 31, 2024
  • Net Profit
    -$280.88 M (USD)
    57.87
    as on Mar 31, 2024
  • EBITDA
    -$155.85 M (USD)
    19.44
    as on Mar 31, 2024
  • Total Equity Funding
    $943.53 M (USD)

    in 21 rounds

  • Latest Funding Round
    $20 M (USD), Post-IPO

    Nov 03, 2023

  • Investors
    Google

    & 20 more

  • Employee Count
    265

    as on Mar 31, 2024

  • Investments & Acquisitions
  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of 23andMe

23andMe is a publicly listed company on the OTC with ticker symbol MEHCQ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: OTC · Ticker: MEHCQ · Sector: Health technology · USA

Products & Services of 23andMe

23andMe offers a comprehensive portfolio of products and services, including Ancestry Service, Health + Ancestry Service, and 23andMe Premium.

Product name locked
Category locked
Primary

Provides detailed ancestry breakdowns from genetic data.

Product name locked
Category locked
Locked

Offers health insights alongside ancestry reports through genotyping.

Product name locked
Category locked
Locked

Delivers premium reports and features for ongoing genetic health tracking.

People of 23andMe

Headcount 500-1000
Employee Profiles 44
Board Members and Advisors 5
Employee Profiles
People
Rick Heisler
Sr. Corporate Counsel
People
Lisa Isaacson
Director of Accounting
People
Daniel Brakin
Director, Growth Marketing
People
Frank Russo
Chief Security Officer

Unlock access to complete

Board Members and Advisors
people
Jim Frankola
Director
people
Andre Fernandez
Director
people
Mark Jensen
Director
people
Thomas Walper
Director

Unlock access to complete

Funding Insights of 23andMe

23andMe has successfully raised a total of $943.53M across 21 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in 23andMe

23andMe has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Google, Fidelity Investments and Illumina.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Sequoia Capital is engaged in venture capital investments.
Locked Locked Locked
Venture capital investment firm
Locked Locked Locked
Long/short equity hedge fund and VC fim
Locked Locked Locked
Premium access

Investor details for 23andMe

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by 23andMe

23andMe has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CureTogether and Icebreaker Health.

Investments
Premium access

Investment portfolio details for 23andMe

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Provider of remote patient consultation services and online delivery of medical care products
Locked Locked 2014 Locked
Quantitative data on medical conditions is shared by users online.
Locked Locked 2008 Locked
Premium access

Complete acquisition details for 23andMe

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - 23andMe

Premium access

Detailed financials for 23andMe

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

23Andme Comparisons

23andMe Primary company
Description
Provider of genetic test solutions to study ancestry, geneal...
Location
Sunnyvale, United States
Founded Year
2006
Annual Revenue
$189.9 M (USD)
Net Profit
-$280.88 M (USD)
EBITDA
-$155.85 M (USD)
Employees
265
As of 2024
Premium access

Peer comparison for 23andMe

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of 23andMe

23andMe operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ancestry, Color, Veritas Genetics, Genoplan and GEDmatch, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of an online genealogy platform offering a host of services
Locked Locked Locked
Cancer care is delivered through a virtual clinic by Color.
Locked Locked Locked
Genetic testing products for health risks and traits are offered.
Locked Locked Locked
Developer of genetic test kits for health analysis
Locked Locked Locked
DNA-based health risk assessment platform
Premium access

Detailed competitors of 23andMe

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on 23Andme

Premium access

Complete news archive for 23andMe

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about 23andMe

23andMe was founded in 2006 and raised its 1st funding round 1 year after it was founded.

23andMe is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.

23andMe is a funded company, having raised a total of $943.53M across 21 funding rounds to date.

As of Mar 31, 2024, the latest employee count at 23andMe is 265.

Annual revenue of 23andMe is $189.9M as on Mar 31, 2024.

23andMe was founded in 2006 in Sunnyvale, United States, within the biotechnology sector. Genetic testing services are offered through its platform to analyze individual ancestry, genealogy, and inherited traits. User data is collected, categorized, and supplied in searchable formats to researchers and scientists for further study. Operations focus on direct-to-consumer testing and data aggregation, primarily serving the U.S. market.

23andMe's top competitors include Ancestry, Veritas Genetics and Color.

23andMe offers Ancestry Service, Health + Ancestry Service, and 23andMe Premium.

Yes, 23andMe is publicly traded on OTC under the ticker symbol MEHCQ.

23andMe has made 2 acquisitions, including CureTogether, and Icebreaker Health.

23andMe has 21 investors. Key investors include Google, Fidelity Investments, Illumina, NIH, and HHS.

The ticker symbol of 23andMe is MEHCQ on OTC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available